Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents.
暂无分享,去创建一个
[1] J. Trojanowski,et al. IBOX(2-(4'-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain. , 2001, Nuclear Medicine and Biology.
[2] A. Alavi,et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] Biodistribution and radiation dosimetry of radioiodinated-SCH 23982, a potential dopamine D-1 receptor imaging agent. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] M. Roberts,et al. Experimental methods for studying drug uptake in the head and brain. , 2000, Current drug metabolism.
[5] M. Kilberg,et al. Molecular biology of mammalian amino acid transporters. , 1996, Annual review of biochemistry.
[6] R. Kessler,et al. (S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-[125I]iodo- 2-methoxybenzamide hydrochloride, a new selective radioligand for dopamine D-2 receptors. , 1988, Journal of medicinal chemistry.
[7] Kengo Ito,et al. Synthesis and preliminary evaluation of [11C]NE-100 labeled in two different positions as a PET sigma receptor ligand. , 1998, Nuclear medicine and biology.
[8] Betz Al,et al. Epithelial properties of brain capillary endothelium. , 1985 .
[9] D. Begley,et al. The Blood‐brain Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System , 1996, The Journal of pharmacy and pharmacology.
[10] H. Tanaka,et al. Drug-protein binding and blood-brain barrier permeability. , 1999, The Journal of pharmacology and experimental therapeutics.
[11] D Mackay,et al. A novel method for measuring membrane-water partition coefficients of hydrophobic organic chemicals: comparison with 1-octanol-water partitioning. , 1988, Journal of Pharmacy and Science.
[12] J. Mukherjee,et al. Development of N-[3-(2',4'-dichlorophenoxy)-2-18F-fluoropropyl]-N-methylpropargylamine (18F-fluoroclorgyline) as a potential PET radiotracer for monoamine oxidase-A. , 1999, Nuclear medicine and biology.
[13] R. Kaliszan,et al. Lipophilicity and pKa estimates from gradient high-performance liquid chromatography. , 2002, Journal of chromatography. A.
[14] C. Crouzel,et al. High specific radioactivity (1R,2S)-4-[(18)F]fluorometaraminol: a PET radiotracer for mapping sympathetic nerves of the heart. , 2000, Nuclear medicine and biology.
[15] P D Leeson,et al. Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. , 1997, Journal of medicinal chemistry.
[16] R. Pleus,et al. Synthesis of (+/-)-[18F]BMY 14802, its enantiomers and their anatomical distributions in rodents. , 1993, Nuclear medicine and biology.
[17] David F. V. Lewis,et al. Baseline Lipophilicity Relationships in Human Cytochromes P450 Associated with Drug Metabolism , 2003, Drug metabolism reviews.
[18] N. Nelson,et al. Structure, function and brain localization of neurotransmitter transporters. , 1994, The Journal of experimental biology.
[19] D. Jewett,et al. (R)‐N‐[11C]methyl‐3‐pyrrolidyl benzilate, a high‐affinity reversible radioligand for PET studies of the muscarinic acetylcholine receptor , 2002, Synapse.
[20] O. Schober,et al. Preparation of 8-[3-(4-fluorobenzoyl)-propyl]-1-(4-[123I] iodobenzoyl)-1,3,8-triazaspiro[4,5]decan-4-one: a novel selective serotonin 5-HT2 receptor agent. , 1997, Nuclear medicine and biology.
[21] G R Wilkinson,et al. Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation. , 1989, The Journal of clinical investigation.
[22] P. Herscovitch,et al. In vivo muscarinic binding of 3‐(alkylthio)‐3‐thiadiazolyl tetrahydropyridines , 1999, Synapse.
[23] H. Onoe,et al. In vitro and in vivo characterization of (+)-3-[11C]cyano-dizocilpine , 1998, Journal of Neural Transmission.
[24] Lipophilicity and biological acitivity. Drug transport and drug distribution in model systems and in biological systems. , 1979, Arzneimittel-Forschung.
[25] Manfred Kansy,et al. Predicting plasma protein binding of drugs: a new approach. , 2002, Biochemical pharmacology.
[26] Bernard Testa,et al. Lipophilicity in Molecular Modeling , 1996, Pharmaceutical Research.
[27] M. Abraham,et al. Rapid-gradient HPLC method for measuring drug interactions with immobilized artificial membrane: comparison with other lipophilicity measures. , 2000, Journal of pharmaceutical sciences.
[28] R. Dannals,et al. 5-[I-125/123]lodo-3(2(S)-azetidinylmethoxy)pyridine, a radioiodinated analog of A-85380 for in vivo studies of central nicotinic acetylcholine receptors. , 1998, Life sciences.
[29] L. Reneman,et al. [123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication , 2000, European Journal of Nuclear Medicine.
[30] D. Greenblatt,et al. In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. , 1983, British journal of anaesthesia.
[31] J. Mcculloch,et al. Synthesis and binding characteristics of N-(1-naphthyl)-N'-(3-[(125)I]-iodophenyl)-N'-methylguanidine ([(125)I]-CNS 1261): a potential SPECT agent for imaging NMDA receptor activation. , 2000, Nuclear medicine and biology.
[32] S. Yalkowsky,et al. Solubility and partitioning VI: octanol solubility and octanol-water partition coefficients. , 1983, Journal of pharmaceutical sciences.
[33] Relative hydrophobicity of organic compounds measured by partitioning in aqueous two-phase systems. , 2000, Journal of chromatography. B, Biomedical sciences and applications.
[34] T. D. Paulis,et al. The Discovery of Epidepride and Its Analogs as High-Affinity Radioligands for Imaging Extrastriatal Dopamine D2 Receptors in Human Brain , 2003 .
[35] Stephen A. Wring,et al. Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.
[36] M. Kilberg,et al. Recent advances in mammalian amino acid transport. , 1993, Annual review of nutrition.
[37] Patrick Poulin,et al. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. , 2002, Journal of pharmaceutical sciences.
[38] J. Korf,et al. Synthesis and organ distribution of [18F]fluoro-Org 6141 in the rat: a potential glucocorticoid receptor ligand for positron emission tomography. , 1995, Nuclear medicine and biology.
[39] B. Kanner,et al. Glutamate transporters from brain , 1993, FEBS letters.
[40] Sylvain Houle,et al. In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. , 2002, Nuclear medicine and biology.
[41] C. Shiue,et al. Comparative PET studies of the distribution of (-)-3,4-methylenedioxy-N-[11C]methamphetamine and (-)-[11C]methamphetamine in a monkey brain. , 1995, Nuclear medicine and biology.
[42] J. Holden,et al. Synthesis and preliminary evaluation of 18F-labeled 4-thia palmitate as a PET tracer of myocardial fatty acid oxidation , 2000 .
[43] M. Danhof,et al. Drug transport across the blood-brain barrier , 1992, Pharmaceutisch Weekblad.
[44] M. Welch,et al. Oxohexestrol derivatives labeled with fluorine-18. Synthesis, receptor binding and in vivo distribution of two non-steroidal estrogens as potential breast tumor imaging agents. , 1994, Nuclear medicine and biology.
[45] S. Kushner,et al. Specificity of diastereomers of [99mTc]TRODAT-1 as dopamine transporter imaging agents. , 1998, Journal of medicinal chemistry.
[46] Martin P. Payne,et al. COMPARISON OF MODELS FOR THE ESTIMATION OF BIOLOGICAL PARTITION COEFFICIENTS , 2002, Journal of toxicology and environmental health. Part A.
[47] M. Welch,et al. Radiosynthesis, in vitro validation, and in vivo evaluation of 18F-labeled COX-1 and COX-2 inhibitors. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[48] S. Houle,et al. Characterization of r-[11C]rolipram for PET imaging of phosphodieterase-4: in vivo binding, metabolism, and dosimetry studies in rats. , 2001, Nuclear medicine and biology.
[49] D. Kuhl,et al. [18F]fluoroethoxy‐benzovesamicol, a PET radiotracer for the vesicular acetylcholine transporter and cholinergic synapses , 1998, Synapse.
[50] H. Minn,et al. Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography , 2000, European Journal of Nuclear Medicine.
[51] M. Welch,et al. Synthesis and evaluation of two positron-labeled nitric oxide synthase inhibitors, S-[11C]methylisothiourea and S-(2-[18F]fluoroethyl)isothiourea, as potential positron emission tomography tracers. , 1996, Journal of medicinal chemistry.
[52] K. Dill,et al. Solute partitioning into lipid bilayer membranes. , 1988, Biochemistry.
[53] H. Kung,et al. Neutral and stereospecific Tc-99m complexes: [99mTc]N-benzyl-3,4-di-(N-2-mercaptoethyl)-amino-pyrrolidines (P-BAT). , 1999, Nuclear medicine and biology.
[54] B. Christian,et al. Radiosynthesis and in vitro evaluation of 2-(N-alkyl-N-1'-11C-propyl)amino-5-hydroxytetralin analogs as high affinity agonists for dopamine D-2 receptors. , 1999, Nuclear medicine and biology.
[55] B. Testa,et al. Determination of Lipophilicity and Hydrogen‐bond Donor Acidity of Bioactive Sulphonyl‐containing Compounds by Reversed‐phase HPLC and Centrifugal Partition Chromatography and their Application to Structure‐activity Relations , 1991, The Journal of pharmacy and pharmacology.
[56] M. Kilbourn,et al. The role of species-dependent metabolism in the regional brain retention of 18F-labeled muscarinic acetylcholine receptor ligands. , 2001, Nuclear medicine and biology.
[57] B. Zeeberg,et al. In vitro and in vivo m2 muscarinic subtype selectivity of some dibenzodiazepinones and pyridobenzodiazepinones , 2000, Brain Research.
[58] P. Schubiger,et al. 123I-labeling and evaluation of Ro 43-0463, a SPET tracer for MAO-B imaging. , 1995, Nuclear medicine and biology.
[59] A. Lázníčková,et al. The effect of lipophilicity on the protein binding and blood cell uptake of some acidic drugs. , 1995, Journal of pharmaceutical and biomedical analysis.
[60] D. Siluk,et al. Chromatographic retention parameters in medicinal chemistry and molecular pharmacology. , 2003, Current medicinal chemistry.
[61] T. Conway,et al. Synthesis and preliminary evaluation of (S)-(2-[18F]fluoro-4,5-dihydroxyphenyl)-2-methyl L-alanine, (S)-[18F]-FMEDOPA, a potentially improved imaging agent for the presynaptic dopaminergic nervous system. , 1996, Nuclear medicine and biology.
[62] S. Stone-Elander,et al. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants. , 1999, Life sciences.
[63] Han van de Waterbeemd,et al. Substructure and whole molecule approaches for calculating log P , 2001, J. Comput. Aided Mol. Des..
[64] W. J. Lambert,et al. Development of a Preformulation Lipophilicity Screen Utilizing a C-18-Derivatized Polystyrene-Divinylbenzene High-Performance Liquid Chromatographic (HPLC) Column , 1990, Pharmaceutical Research.
[65] J. Lin,et al. Effects of protein binding and experimental disease states on brain uptake of benzodiazepines in rats. , 1990, The Journal of pharmacology and experimental therapeutics.
[66] L. Aarons,et al. Quantitative Structure-Pharmacokinetics Relationships: I. Development of a Whole-Body Physiologically Based Model to Characterize Changes in Pharmacokinetics Across a Homologous Series of Barbiturates in the Rat , 1997, Journal of Pharmacokinetics and Biopharmaceutics.
[67] Rikki N. Waterhouse,et al. Halogenated 4-(phenoxymethyl)piperidines as potential radiolabeled probes for σ-1 receptors : In vivo evaluation of [123I]-1-(iodopropen-2-yl)-4-[(4-cyanophenoxy)methyl]piperidine , 1997 .
[68] J. Tillement,et al. Drug transfer across the blood‐brain barrier and improvement of brain delivery , 1999, Fundamental & clinical pharmacology.
[69] R. Pignatello,et al. Lipophilicity evaluation by RP-HPLC of two homologous series of methotrexate derivatives. , 2000, Pharmaceutica Acta Helvetiae.
[70] H. Kubinyi. Nonlinear dependence of biological activity on hydrophobic character: the bilinear model. , 1979, Il Farmaco; edizione scientifica.
[71] P. Dessen,et al. Drug-binding properties of rat alpha 1-foetoprotein. Binding of warfarin, phenylbutazone, azapropazone, diazepam, digitoxin and cholic acid. , 1984, Biochemical Journal.
[72] Han van de Waterbeemd,et al. Lipophilicity in PK design: methyl, ethyl, futile , 2001, J. Comput. Aided Mol. Des..
[73] D. Scherman,et al. High lipophilicity decreases drug transport across intestinal epithelial cells. , 1994, The Journal of pharmacology and experimental therapeutics.
[74] M. Raichle,et al. Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[75] B. Testa,et al. Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques , 2002, Cellular and Molecular Life Sciences CMLS.
[76] Hartwig Wolburg,et al. Tight junctions of the blood-brain barrier: development, composition and regulation. , 2002, Vascular pharmacology.
[77] Alan A. Wilson,et al. An admonition when measuring the lipophilicity of radiotracers using counting techniques. , 2001, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[78] M. Laruelle,et al. In vivo evaluation of [11C]-3-[2-[(3-methoxyphenylamino)carbonyl]ethenyl]-4,6-dichloroindole-2-carboxylic acid ([11C]3MPICA) as a PET radiotracer for the glycine site of the NMDA ion channel. , 2002, Nuclear medicine and biology.
[79] Alan A. Wilson,et al. Comparative Evaluation in Nonhuman Primates of Five PET Radiotracers for Imaging the Serotonin Transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[80] D. Wong,et al. Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon. , 1999, Nuclear medicine and biology.
[81] J. Viña,et al. The Complementary Membranes Forming the Blood‐Brain Barrier , 2002, IUBMB life.
[82] M. Laruelle,et al. Simplified multidose preparation of iodine-123-beta-CIT: a marker for dopamine transporters. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[83] R. Mach,et al. Synthesis and biological characterization of stable and radioiodinated (+/-)-trans-2-hydroxy-3-P[4-(3-iodophenyl)piperidyl]-1,2,3,4-tetrahydronaphthalene (3'-IBVM). , 2000, Nuclear medicine and biology.
[84] A. Lammertsma,et al. Development of central 5-HT2A receptor radioligands for PET: comparison of [3H]RP 62203 and [3H]SR 46349B kinetics in rat brain. , 1996, Nuclear medicine and biology.
[85] H. Matsuda,et al. Radioiodinated (—)-2-[4-(3‐iodophenyl) piperidino] cyclohexanol: A potential radioligand for mapping presynaptic cholinergic neurons , 1996, Nuclear medicine communications.
[86] Peter L. Bonate,et al. Animal models for studying transport across the blood-brain barrier , 1995, Journal of Neuroscience Methods.
[87] R. G. Manning,et al. Evaluation of 5‐[18F]Fluoropropylepidepride as a potential pet radioligand for imaging dopamine D2 receptors , 1993, Synapse.
[88] M. Senda,et al. Synthesis and preliminary evaluation of a carbon-11-labeled adenosine transporter blocker [11C]KF21652 , 2001 .
[89] Y. Magata,et al. Evaluation of N-alkyl derivatives of radioiodinated spiperone as radioligands for in vivo dopamine D2 receptor studies: effects of lipophilicity and receptor affinity on the in vivo biodistribution. , 1992, Chemical & pharmaceutical bulletin.
[90] Determination of octanol‐water partition coefficients for carbonate esters and other small organic molecules by microemulsion electrokinetic chromatography , 2003, Electrophoresis.
[91] R. Lew,et al. N-(6-18F-fluorohexyl)-N-methylpropargylamine: a fluorine-18-labeled monoamine oxidase B inhibitor for potential use in PET studies. , 1999, Nuclear medicine and biology.
[92] M. K. Das,et al. Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. , 1995, Nuclear medicine and biology.
[93] R. Rogers,et al. Partitioning of small organic molecules in aqueous biphasic systems. , 1998, Journal of chromatography. B, Biomedical sciences and applications.
[94] K. Taguchi,et al. Synthesis and evaluation of radiolabeled piperazine derivatives of vesamicol as SPECT agents for cholinergic neurons. , 2001, Nuclear medicine and biology.
[95] J. Baron,et al. Specific in vivo binding in the rat brain of [18F]RP 62203: a selective 5-HT2A receptor radioligand for positron emission tomography. , 1996, Nuclear medicine and biology.
[96] J. Bading,et al. Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[97] J R Chretien,et al. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. , 1998, Journal of drug targeting.
[98] G Folkers,et al. Review of theoretical passive drug absorption models: historical background, recent developments and limitations. , 1996, Pharmaceutica acta Helvetiae.
[99] Alex Avdeef,et al. Physicochemical Profiling (Solubility, Permeability and Charge State) , 2001 .
[100] H. M. Solomon,et al. A rapid method for the estimation of drug‐albumin affinity constants in human plasma , 1971, Clinical pharmacology and therapeutics.
[101] M. Welch,et al. 11 beta-methoxy-, 11 beta-ethyl- and 17 alpha-ethynyl-substituted 16 alpha-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity. , 1990, Journal of medicinal chemistry.
[102] M. Hediger,et al. Introduction: glutamate transport, metabolism, and physiological responses. , 1999, The American journal of physiology.
[103] M. Goodman,et al. In vivo evaluation of [123I]-8-[4-[2-(5-iodothienyl)]-4-oxobutyl]-3-methyl-1-phenyl-1,3 ,8-tri azaspiro[4.5]decan-4-one as a potential dopamine D2 receptor radioligand for SPECT. , 1998, Nuclear medicine and biology.
[104] Mark E. Schmidt,et al. Evaluation of [3H]LY341495 for labeling group II metabotropic glutamate receptors in vivo. , 2003, Nuclear medicine and biology.
[105] M. Kassiou,et al. Pharmacological evaluation of (S)-8-[123I]iodobretazenil: a radioligand for in vivo studies of central benzodiazepine receptors. , 2003, Nuclear medicine and biology.
[106] S. Ametamey,et al. SYNTHESIS AND IN VITRO AND IN VIVO EVALUATION OF [11C]METHYL-BIII277CL FOR IMAGING THE PCP-BINDING SITE OF THE NMDA RECEPTOR BY PET , 2002, Journal of receptor and signal transduction research.
[107] R. Bendayan,et al. Functional expression and localization of P‐glycoprotein at the blood brain barrier , 2002, Microscopy research and technique.
[108] R. Waterhouse,et al. In vivo evaluation of [18F]1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine: a selective sigma-1 receptor radioligand for PET. , 1997, Nuclear medicine and biology.
[109] M. Otagiri,et al. Species Differences of Serum Albumins: I. Drug Binding Sites , 1997, Pharmaceutical Research.
[110] André Luxen,et al. Effect of endogenous serotonin on the binding of the 5‐HT1A PET ligand 18F‐MPPF in the rat hippocampus: kinetic β measurements combined with microdialysis , 2002, Journal of neurochemistry.
[111] B. Shroot,et al. Determination of partition coefficients of glucocorticosteroids by high-performance liquid chromatography. , 1984, Journal of pharmaceutical sciences.
[112] N. Guo,et al. Pharmacokinetics and brain distribution in non human primate of R(-)[123I]DOI, A 5HT(2A/2C) serotonin agonist. , 2002, Nuclear medicine and biology.
[113] A. Horti,et al. Synthesis and evaluation of a novel series of 2-chloro-5-((1-methyl-2-(S)-pyrrolidinyl)methoxy)-3-(2-(4-pyridinyl)vinyl)pyridine analogues as potential positron emission tomography imaging agents for nicotinic acetylcholine receptors. , 2002, Journal of medicinal chemistry.
[114] G R Wilkinson,et al. Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. , 1988, The Journal of pharmacology and experimental therapeutics.
[115] M. Kiyosawa,et al. Carbon-11-labeled KF21213: a highly selective ligand for mapping CNS adenosine A(2A) receptors with positron emission tomography. , 2000, Nuclear medicine and biology.
[116] D. Rockey,et al. Preliminary evaluation of 15-[18F]fluoro-3-oxa-pentadecanoate as a PET tracer of hepatic fatty acid oxidation. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[117] M. Welch,et al. Biodistribution of N-alkyl and N-fluoroalkyl derivatives of spiroperidol; radiopharmaceuticals for PET studies of dopamine receptors. , 1986, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[118] T. Suhara,et al. Synthesis, in vitro and in vivo pharmacology of a C-11 labeled analog of CP-101,606, (+/-)threo-1-(4-hydroxyphenyl)-2-[4-hydroxy-4-(p-[11C]methoxyphenyl)piperidino]-1-propanol, as a PET tracer for NR2B subunit-containing NMDA receptors. , 2002, Nuclear medicine and biology.
[119] H. Minn,et al. Pharmacokinetics of [18F]FETNIM: A Potential Hypoxia Marker for PET , 2001 .
[120] U. Kragh-Hansen,et al. Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands. , 1988, Molecular pharmacology.
[121] P. Ruelle. The n-octanol and n-hexane/water partition coefficient of environmentally relevant chemicals predicted from the mobile order and disorder (MOD) thermodynamics. , 2000, Chemosphere.
[122] P. Carnochan,et al. Radiolabelled 5'-iodo-2'-deoxyuridine: a promising alternative to [18F]-2-fluoro-2-deoxy-D-glucose for PET studies of early response to anticancer treatment. , 1999, Nuclear medicine and biology.
[123] M. Palkovits,et al. Localization and Dynamic Regulation of Biogenic Amine Transporters in the Mammalian Central Nervous System , 1998, Frontiers in Neuroendocrinology.
[124] A. Tsantili-Kakoulidou,et al. Synthesis, lipophilicity and biological evaluation of indole-containing derivatives of 1,3,4-thiadiazole and 1,2, 4-triazole. , 1998, Farmaco.
[125] D. Drayer. Lipophilicity, Hydrophilicity, and the Central Nervous System Side Effects of Beta Blockers , 1987, Pharmacotherapy.
[126] Benjamin Ehrenberg,et al. Do Liposome-binding Constants of Porphyrins Correlate with Their Measured and Predicted Partitioning Between Octanol and Water?¶ , 2002, Photochemistry and photobiology.
[127] C. Dence,et al. Synthesis, in vivo evaluation and PET study of a carbon-11-labeled neuronal nitric oxide synthase (nNOS) inhibitor S-methyl-L-thiocitrulline. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[128] S. Yalkowsky,et al. Solubility and partitioning IV: Aqueous solubility and octanol-water partition coefficients of liquid nonelectrolytes. , 1981, Journal of pharmaceutical sciences.
[129] D. Charney,et al. Comparison of [123I]ß-CIT and [123I]IPCIT as single-photon emission tomography radiotracers for the dopamine transporter in nonhuman primates , 2005, European Journal of Nuclear Medicine.
[130] Synthesis and evaluation of racemic [(11)C]NS2456 and enantiomers as selective serotonin reuptake radiotracers for PET. , 2001, Nuclear medicine and biology.